Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Lipid-based Nanocarriers for Cancer and Tumor Treatment

Author(s): Mohammed Tahir Ansari*, Thiya Anissa Ramlan, Nurul Nadia Jamaluddin, Nurshahiera Zamri, Roshan Salfi, Abdullah Khan, Farheen Sami, Shahnaz Majeed and M. Saquib Hasnain

Volume 26, Issue 34, 2020

Page: [4272 - 4276] Pages: 5

DOI: 10.2174/1381612826666200720235752

Price: $65

Abstract

Cancer and tumor have been major reasons for numerous deaths in this century across the world. Many strategies have been designed to treat, diagnose, or prevent cancer. The success of chemotherapy largely depends on drug targeting. The advent of nanotechnology has vastly improved drug delivery for targeting and diagnosis. Nevertheless, the accuracy of drug targeting with polymeric nanoparticles has always been questionable. The polymeric nanoparticles synthesized from varieties of lipid-based compounds or combined with vectors, such as liposomes, ethosomes, and transfersomes, may allow the drug to overcome the issue of resistance to drug absorption in biological membranes. The combined effects of lipid-based nanocarriers are known to improve the efficacy and accuracy of polymeric nanoparticles. The present review explores the application of lipid based nanocarriers in the treatment and diagnosis of cancer A special focus is given to the use of lipid-based nanocarriers in the treatment, diagnosis, and mitigation of cancer located in blood, brain, lung, and colon. The treatment of these cancers has always been questionable as the chances of relapse are very high. The review encompasses the use of lipid-based nanocarriers in targeting tissue-specific cancer cells.

Keywords: Chemotherapy, tumor, lipid-based, targeting tissue, health issue, cross biological.

« Previous Next »
[1]
Deep P, Singh AK, Ansari MT, Raghav P. Pharmacological Potentials of Ficus racemosa-A Review. Int J Pharm Sci Rev Res 2013; 22(6): 29-34.
[2]
Ansari T, Farheen M, Hoda MN, Nayak AK. Microencapsulation of pharmaceuticals by solvent evaporation technique: A review. Elixir Pharmacy 2012; 47: 8821-7.
[3]
Mohammed Tahir A, Farheen S, Fatin Amalina K, et al. Medical applications of Zinc nanoparticles. Curr Nanomed 2018.
[4]
Majeed S. bin Abdullah MS, Nanda A, Ansari MT. In vitro study of the antibacterial and anticancer activities of silver nanoparticles synthesized from Penicillium brevicompactum (MTCC-1999). J Taibah University Sci 2016; 10: 614-20.
[http://dx.doi.org/10.1016/j.jtusci.2016.02.010]
[5]
Majeed S, Abdullah MS, Dash GK, Ansari MT, Nanda A. Biochemical synthesis of silver nanoprticles using filamentous fungi Penicillium decumbens (MTCC-2494) and its efficacy against A-549 lung cancer cell line. Chin J Nat Med 2016; 14(8): 615-20.
[http://dx.doi.org/10.1016/S1875-5364(16)30072-3] [PMID: 27608951]
[6]
Hasnain MS, Nayak AK, Singh M, Tabish M, Ansari MT, Ara TJ. Alginate-based bipolymeric-nanobioceramic composite matrices for sustained drug release. Int J Biol Macromol 2016; 83: 71-7.
[http://dx.doi.org/10.1016/j.ijbiomac.2015.11.044] [PMID: 26608007]
[7]
Ansari MT. ibrahim Nbd, Tahir F, Majeed S, Hasnain MS, Badgujar VB. Design and evaluation of topical herbal antifungal stick containing extract of Rhinacanthus nasutus. J Herb Med 2019; 17-8: 100290.
[http://dx.doi.org/10.1016/j.hermed.2019.100290]
[8]
Jahangir MA, Gilani SJ, Muheem A, et al. Quantum dots: Next generation of smart nano-systems. Pharm Nanotechnol 2019; 7: 1-12.
[9]
Majeed S, Danish M, Ismail MHB, Ansari MT, Ibrahim MNM. Anticancer and apoptotic activity of biologically synthesized zinc oxide nanoparticles against human colon cancer HCT-116 cell linein vitro study. Sustainable Chemistry Pharmacy 2019; 14: 100179.
[http://dx.doi.org/10.1016/j.scp.2019.100179]
[10]
Gurudutta P, Parmar JU, Sajid AM, Tahir AM. Self-emulsifying drug delivery systems: an attempt to improve oral absorption of poorly soluble drugs. Res J Pharm Dos Forms Technol 2010; 2: 206-14.
[11]
Banavath H, Sivarama R, Ansari T, Ali S, Pattnaik G. Nanosuspension: an attempt to enhance bioavailability of poorly soluble drugs. Int J Pharm Sci Res 2010; 1: 1-11.
[12]
Crommelin DJA, Fransen GJ, Salemink PJM. Stability of liposomes on storage. Gregoriadis G, Senior J, Poste G, eds, Targeting of Drugs With Synthetic Systems. Springer US: Boston, MA 1986; 277-87.
[http://dx.doi.org/10.1007/978-1-4684-5185-6_20]
[13]
Chaudhary Z, Ahmed N. ur.Rehman A, Khan GM. Lipid polymer hybrid carrier systems for cancer targeting: A review. Int J Polymeric Mater Polymer Biomater 2018; 67: 86-100.
[http://dx.doi.org/10.1080/00914037.2017.1300900]
[14]
Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipid-polymer hybrid nanoparticles as a nextgeneration drug delivery platform: state of the art, emerging technologies, and perspectives. Int J Nanomedicine 2019; 14: 1937-52.
[http://dx.doi.org/10.2147/IJN.S198353] [PMID: 30936695]
[15]
Hallan SS, Kaur P, Kaur V, Mishra N, Vaidya B. Lipid polymer hybrid as emerging tool in nanocarriers for oral drug delivery. Artif Cells Nanomed Biotechnol 2016; 44(1): 334-49.
[http://dx.doi.org/10.3109/21691401.2014.951721] [PMID: 25237838]
[16]
Hadinoto K, Sundaresan A, Cheow WS. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 2013; 85(3 Pt A): 427-43.
[http://dx.doi.org/10.1016/j.ejpb.2013.07.002] [PMID: 23872180]
[17]
Peer D. Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv Drug Deliv Rev 2012; 64(15): 1738-48.
[http://dx.doi.org/10.1016/j.addr.2012.06.013] [PMID: 22820531]
[18]
Zhu B, Zhang H, Yu L. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation. Biomed Pharmacother 2017; 86: 547-54.
[http://dx.doi.org/10.1016/j.biopha.2016.11.121] [PMID: 28024291]
[19]
Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drugnanoparticles? Drug Discov Today 2008; 13(23-24): 1099-106.
[http://dx.doi.org/10.1016/j.drudis.2008.09.005] [PMID: 18848640]
[20]
Bourseau-Guilmain E, Béjaud J, Griveau A, et al. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Int J Pharm 2012; 423(1): 93-101.
[http://dx.doi.org/10.1016/j.ijpharm.2011.06.001] [PMID: 21683129]
[21]
Ramishetti S, Landesman-Milo D, Peer D. Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. J Drug Target 2016; 24(9): 780-6.
[http://dx.doi.org/10.3109/1061186X.2016.1172587] [PMID: 27030014]
[22]
Huang X, Schwind S, Yu B, et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res 2013; 19(9): 2355-67.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-3191] [PMID: 23493348]
[23]
Yang Z, Yu B, Zhu J, et al. A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia. Nanoscale 2014; 6(16): 9742-51.
[http://dx.doi.org/10.1039/C4NR01510J] [PMID: 25003978]
[24]
Durfee PN, Lin Y-S, Dunphy DR, et al. Mesoporous silica nanoparticle-supported lipid bilayers (Protocells) for active targeting and delivery to individual leukemia cells. ACS Nano 2016; 10(9): 8325-45.
[http://dx.doi.org/10.1021/acsnano.6b02819] [PMID: 27419663]
[25]
Khajavinia A, Varshosaz J, Dehkordi AJ. Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. Nanotechnology 2012; 23(40): 405101.
[http://dx.doi.org/10.1088/0957-4484/23/40/405101] [PMID: 22983592]
[26]
He W, Bennett MJ, Luistro L, et al. Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability. Mol Ther 2014; 22(2): 359-70.
[http://dx.doi.org/10.1038/mt.2013.210] [PMID: 24002693]
[27]
Banerjee A, Pathak S, Subramanium VD. G D, Murugesan R, Verma RS. Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discov Today 2017; 22(8): 1224-32.
[http://dx.doi.org/10.1016/j.drudis.2017.05.006] [PMID: 28545838]
[28]
You X, Kang Y, Hollett G, et al. Polymeric nanoparticles for colon cancer therapy: overview and perspectives. J Mater Chem B Mater Biol Med 2016; 4(48): 7779-92.
[http://dx.doi.org/10.1039/C6TB01925K] [PMID: 32263770]
[29]
Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012; 64(6): 557-70.
[http://dx.doi.org/10.1016/j.addr.2011.12.009] [PMID: 22212900]
[30]
Wilson DS, Dalmasso G, Wang L, Sitaraman SV, Merlin D, Murthy N. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 2010; 9(11): 923-8.
[http://dx.doi.org/10.1038/nmat2859] [PMID: 20935658]
[31]
Tummala S, Gowthamarajan K, Satish Kumar MN, Wadhwani A. Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors. Drug Deliv 2016; 23(5): 1773-87.
[http://dx.doi.org/10.3109/10717544.2015.1084400] [PMID: 26377238]
[32]
Yassin AEB, Anwer MK, Mowafy HA, El-Bagory IM, Bayomi MA, Alsarra IA. Optimization of 5-flurouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer. Int J Med Sci 2010; 7(6): 398-408.
[http://dx.doi.org/10.7150/ijms.7.398] [PMID: 21103076]
[33]
Li L, Xiang D, Shigdar S, et al. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells. Int J Nanomedicine 2014; 9: 1083-96.
[PMID: 24591829]
[34]
Serpe L, Catalano MG, Cavalli R, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 2004; 58(3): 673-80.
[http://dx.doi.org/10.1016/j.ejpb.2004.03.026] [PMID: 15451544]
[35]
Sundaramoorthy P, Ramasamy T, Mishra SK, et al. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells. Acta Biomater 2016; 42: 220-31.
[http://dx.doi.org/10.1016/j.actbio.2016.07.006] [PMID: 27395829]
[36]
Zhang M, Xiao B, Wang H, et al. Edible ginger-derived nano-lipids loaded with doxorubicin as a novel drug-delivery approach for colon cancer therapy. Mol Ther 2016; 24(10): 1783-96.
[http://dx.doi.org/10.1038/mt.2016.159] [PMID: 27491931]
[37]
Mandal B, Bhattacharjee H, Mittal N, et al. Core-shell-type lipidpolymer hybrid nanoparticles as a drug delivery platform. Nanomedicine (Lond) 2013; 9(4): 474-91.
[http://dx.doi.org/10.1016/j.nano.2012.11.010] [PMID: 23261500]
[38]
Prabhu RH, Patravale VB, Joshi MD. Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine 2015; 10: 1001-18.
[PMID: 25678788]
[39]
Gao J, Xia Y, Chen H, et al. Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma. Nanomedicine (Lond) 2014; 9(2): 279-93.
[http://dx.doi.org/10.2217/nnm.13.20] [PMID: 23721168]
[40]
Zhang J, Hu J, Chan HF, Skibba M, Liang G, Chen M. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. Nanomedicine (Lond) 2016; 12(5): 1303-11.
[http://dx.doi.org/10.1016/j.nano.2016.01.017] [PMID: 26964482]
[41]
Díez S, Navarro G. In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. J Gene Medicine 2009; 11: 38-45.
[42]
Zhang J, Wang T, Mu S, Olerile LD, Yu X, Zhang N. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy. Nanomedicine (Lond) 2017; 12(8): 911-25.
[http://dx.doi.org/10.2217/nnm-2016-0402] [PMID: 28339312]
[43]
Su X, Wang Z, Li L, et al. Lipid-polymer nanoparticles encapsulating doxorubicin and 2′-deoxy-5-azacytidine enhance the sensitivity of cancer cells to chemical therapeutics. Mol Pharm 2013; 10(5): 1901-9.
[http://dx.doi.org/10.1021/mp300675c] [PMID: 23570548]
[44]
Du JB, Song YF, Ye WL, et al. PEG-detachable lipid-polymer hybrid nanoparticle for delivery of chemotherapy drugs to cancer cells. Anticancer Drugs 2014; 25(7): 751-66.
[http://dx.doi.org/10.1097/CAD.0000000000000092] [PMID: 24590167]
[45]
Zheng M, Yue C, Ma Y, et al. Single-step assembly of DOX/ICG loaded lipid--polymer nanoparticles for highly effective chemophotothermal combination therapy. ACS Nano 2013; 7(3): 2056-67.
[http://dx.doi.org/10.1021/nn400334y] [PMID: 23413798]
[46]
Madni A, Batool A, Noreen S, et al. Novel nanoparticulate systems for lung cancer therapy: an updated review. J Drug Target 2017; 25(6): 499-512.
[http://dx.doi.org/10.1080/1061186X.2017.1289540] [PMID: 28151021]
[47]
Mottaghitalab F, Farokhi M, Fatahi Y, Atyabi F, Dinarvand R. New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment. J Control Release 2019; 295: 250-67.
[http://dx.doi.org/10.1016/j.jconrel.2019.01.009] [PMID: 30639691]
[48]
Shi J, Xu Y, Xu X, et al. Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing. Nanomedicine (Lond) 2014; 10(5): 897-900.
[http://dx.doi.org/10.1016/j.nano.2014.03.006] [PMID: 24650883]
[49]
Zhu X, Xu Y, Solis LM, et al. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci USA 2015; 112(25): 7779-84.
[http://dx.doi.org/10.1073/pnas.1505629112] [PMID: 26056316]
[50]
Mandal B, Mittal NK, Balabathula P, Thoma LA, Wood GC. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer. Eur J Pharm Sci 2016; 81: 162-71.
[http://dx.doi.org/10.1016/j.ejps.2015.10.021] [PMID: 26517962]
[51]
Guo Y, Wang L, Lv P, Zhang P. Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer. Oncol Lett 2015; 9(3): 1065-72.
[http://dx.doi.org/10.3892/ol.2014.2840] [PMID: 25663858]
[52]
Wang G, Wang Z, Li C, et al. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipidpolymer nanoparticles for the enhanced lung cancer therapy. Biomed Pharmacother 2018; 106: 275-84.
[http://dx.doi.org/10.1016/j.biopha.2018.06.137] [PMID: 29966971]
[53]
Kabary DM, Helmy MW, Elkhodairy KA, Fang J-Y, Elzoghby AO. Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma. Colloids Surf B Biointerfaces 2018; 169: 183-94.
[http://dx.doi.org/10.1016/j.colsurfb.2018.05.008] [PMID: 29775813]
[54]
Kim J, Ramasamy T, Choi JY, et al. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in nonsmall cell lung cancer. Colloids Surf B Biointerfaces 2017; 150: 393-401.
[http://dx.doi.org/10.1016/j.colsurfb.2016.11.002] [PMID: 27825759]
[55]
Zhou J, Sun J, Chen H, Peng Q. Promoted delivery of salinomycin sodium to lung cancer cells by dual targeting PLGA hybrid nanoparticles. Int J Oncol 2018; 53(3): 1289-300.
[http://dx.doi.org/10.3892/ijo.2018.4474] [PMID: 30015824]

Rights & Permissions Print Cite
Article Metrics
15
© 2024 Bentham Science Publishers | Privacy Policy